11:19 AM EDT, 06/24/2024 (MT Newswires) -- InflaRx ( IFRX ) said Monday that the Biomedical Advanced Research and Development Authority has selected its anti-inflammatory drug Gohibic, or vilobelimab, for a Phase 2 clinical trial evaluating options to treat acute respiratory distress syndrome.

The trial, expected to start later this year, will assess 600 hospitalized adults and the primary endpoint is all-cause mortality at day 28, the company said.

Vilobelimab will be one of the three investigational drugs evaluated in the study and each group is expected to enroll 100 patients on investigational drug and 100 patients on placebo, the company said.

Shares of the company were up more than 10% in recent trading.

Price: 1.70, Change: +0.16, Percent Change: +10.39